The efficacy of TKIs in treatment of human primary small cell lung cancer xenograft model in vivo

• Published in: Zhongguo ying yong sheng li xue za zhi Vol. 32; no. 6; p. 525
• Main Authors: Yu-Hua, Zhang, Liang, Sun, Bin, Liu, Guo-Qiang, L I
• Format: Journal Article
• Language: Chinese
• Published: China 08.06.2016
• Subjects: Afatinib; Animals; Antineoplastic Agents - pharmacology; Carcinoma, Non-Small-Cell Lung - drug therapy; Cell Line, Tumor; Erlotinib Hydrochloride - pharmacology; Gefitinib; Humans; Lung Neoplasms - drug therapy; Mice; Mice, Inbred NOD; Mice, SCID; Protein Kinase Inhibitors - pharmacology; Quinazolines - pharmacology; Xenograft Model Antitumor Assays; Non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice; non-small-cell lung cancer (NSCLC); efficacy; disease model; tyrosine kinase inhibitors (TKIs)
• DOI: 10.13459/j.cnki.cjap.2016.06.009
• ISSN: 1000-6834

To study the treatmaient of non-small cell lung cancer, we established the HU-Prim allograft transplantation tumor model. The fresh tumor samples were transplanted in the right scapular subcutaneous layer of the severe combined immunodeficient Non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice. The pathological features of the tumors were observed. Nonnecrotic tissue was inoculated subcutaneously into the right axillary. When the tumor in burdened rat grew approximately 100 mm , according to the tumor size all the animals were divided into the following four groups, eight rats in each group:solvent control group, gefitinib group (100 mg/kg), erlotinib group (50 mg/kg), afatinib group (20 mg/kg). Aniamals were treated with drugs by intragastric (i.g.) administrated, once daily, for consecutively 14 days. Measure the tumor size 2-3 times every week. HuPrime1-NSCLC mutant sensitive xenograft model research data showed that reversible tyrosine kinase inhibitors gefitinib, erlotinib and irreversibl